Navigation Links
GSK and Pfizer Innovative Agreement Creates Specialist HIV Company
Date:4/16/2009

LONDON, April 16 /PRNewswire-FirstCall/ -- Pharmaceutical companies GlaxoSmithKline and Pfizer today announced an "innovative agreement" to pool their HIV assets creating a new world-leading, specialist HIV company.

The deal will see the drug giants combine their existing HIV product and their pipelines with GSK holding 85% of the company and Pfizer 15%.

The deal will be marginally dilutive to GSK earnings in the first two years but in a video interview Group CEO Andrew Witty said there were longer term benefits for GSK shareholders.

"Today we own 100 per cent of a pipeline with three assets in it. Tomorrow we'll own 85 per cent of a pipeline with somewhere between five and seven assets in it."

The GSK boss said he was also committed to maximising the cost savings from the combination.

The interview and transcript are available now on http://w3.cantos.com/glaxosmithkline.

It's free to view. All you need to do is register at http://www.cantos.com. Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email enquiries@cantos.com or phone +44-207-936-1333.


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Lakewood-Amedex, Inc. Appoints William J. Robison, Former Executive Vice President of Pfizer, as Board Member
2. MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
3. JMAR Technologies' Chief Scientist Invited by Pfizer Inc. to Speak at IFPAC -- BioSentry Makes Strides in Pharma Market
4. Hovione Buys Pfizers Loughbeg API Facility
5. WWMR Announces Pain Clinic Physicians Most Appreciated Companies: Pfizer, Eli Lilly and Endo Pharmaceuticals
6. Stem Cell Sciences Signs Service Agreement With Pfizer to Provide Access to Proprietary Technologies and Methods
7. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
8. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
9. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
10. QSV Biologics awarded cGMP manufacturing contract by Pfizer Inc.
11. Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... ... Do More with OHAUS , With the launch of the new laboratory ... industry, to extending its expertise across the entire laboratory to a range of life ... allowing for its customers to 'Do More' in the lab. , Efficiency and ...
(Date:6/19/2017)... ... June 19, 2017 , ... A colony of healthy ... cells and tissues by delivering pollen and nectar containing nutrients necessary for growth and ... stay healthy. , Many recent indicators point to a decline in honey bee health. ...
(Date:6/15/2017)... ... June 15, 2017 , ... ... a Series B round of financing in the amount of $6 million. An ... investors participated in the round. , The Series B funding will enable Cybrexa ...
(Date:6/14/2017)... , ... June 14, 2017 , ... ... 8th to discuss the initiative steered by the executive search firm, “Building Value ... of the Board of Directors of Foundation Medicine, led an open discussion with ...
Breaking Biology Technology:
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
Breaking Biology News(10 mins):